Introduction
============

COPD frequently leads to dyspnea and reduced exercise tolerance and significantly affects quality of life. COPD has been the focus of clinical research recently because of its steadily increasing prevalence, mortality and disease burden. Estimates show that COPD will become the third leading cause of death worldwide by the year 2030.[@b1-copd-13-1591] In Taiwan, COPD was the seventh leading cause of death in 2013 with a mortality rate of 25.5 per 100,000 and an annual medical cost of 130 million dollars.[@b2-copd-13-1591]

COPD is a common comorbid condition in patients who present for coronary artery bypass graft (CABG) surgery.[@b3-copd-13-1591] COPD has been considered a predictor of poor early outcomes in patients undergoing CABG surgery. Patients with moderate-to-severe COPD have a higher risk of mortality (1.4%) after CABG surgery than patients without COPD (0.7%).[@b4-copd-13-1591]--[@b6-copd-13-1591] Previous studies have shown that there is a greater benefit of preoperative than postoperative physical therapy in patients undergoing CABG surgery.[@b7-copd-13-1591],[@b8-copd-13-1591] The incidence of pulmonary complications such as atelectasis, pleural effusion, pneumonia and respiratory failure in patients undergoing CABG surgery has ranged from 5% to 73% in previous reports.[@b9-copd-13-1591] Atelectasis is common in patients undergoing CABG surgery; this may be due to complex factors, including general anesthesia, diaphragmatic dysfunction and postoperative pain.[@b10-copd-13-1591]

Dysfunction of respiratory muscles due to surgery may also lead to a decrease in vital capacity (VC), tidal volume and total lung capacity. Therefore, respiratory muscle weakness has been found to be correlated with a higher rate of postoperative pulmonary complications, which may be prevented by preoperative inspiratory muscles training.[@b11-copd-13-1591],[@b12-copd-13-1591] Pulmonary dysfunction after CABG surgery is also a well-documented complication with a significant decrease in lung volumes, VC and oxygenation, and a drop in the forced expiratory volume in 1 second (FEV~1~), forced VC (FVC) and functional residual capacity (FRC) by 30%--50%.[@b13-copd-13-1591]--[@b16-copd-13-1591]

During the 1980s and 1990s, the pulmonary rehabilitation program (PRP) involved non-pharmacologic treatment; the pathophysiological rationale was not clearly understood. More recently, PRP has become evidence based and is an important intervention in patients with COPD to improve muscle tone and reduce disability.[@b17-copd-13-1591],[@b18-copd-13-1591] Previous studies have demonstrated the effectiveness of pulmonary training in reducing pulmonary complications. Training techniques include preoperative breathing exercises, respiratory muscle training, spirometry training, postoperative bronchial toileting, early ambulation, lung expansion techniques and spirometry training.[@b19-copd-13-1591],[@b20-copd-13-1591] However, it is unclear whether the effectiveness of PRP after cardiac surgery differs between patients with and without COPD. The purpose of this study was to compare the effectiveness of perioperative PRP in patients with and without COPD who undergo CABG surgery.

Patients and methods
====================

We retrospectively reviewed patients who underwent CABG surgery and received perioperative PRP at the Kaohsiung Chang Gung Memorial Hospital, Taiwan, using electronic charts from January 2009 to December 2013 ([Figure 1](#f1-copd-13-1591){ref-type="fig"}). Patients who underwent emergency surgery, were hemodynamically unstable, were ventilator dependent and had not undergone the full PRP were excluded. We collected data on demographic characteristics, muscle strength, the degree of dyspnea, pulmonary function and postoperative pulmonary complications to compare COPD and non-COPD patients.

PRP
---

The PRP included smoking cessation, breathing exercises (pursed-lip breathing, diaphragmatic breathing and cough training) three times per day, upper and lower limb exercises 30 minutes per day, incentive spirometry (Triflow-II) three times per day, intermittent positive pressure breathing 10--15 minutes per day and chest physical therapy four times per day (chest percussion, chest fibrillation and posture drainage by respiratory therapist). The interventions commenced 1 week prior to surgery and continued for 2 weeks postoperatively.

Evaluation of respiratory muscle strength and degree of dyspnea
---------------------------------------------------------------

We used the modified Borg Scale to evaluate self-perceived degree of dyspnea. Patients rated their degree of dyspnea on a scale of 0--10, with 0 denoting no breathlessness at all and 10 denoting maximum breathlessness. Maximal inspiratory pressure (MIP, cmH~2~O), maximal expiratory pressure (MEP, cmH~2~O) and respiratory rate (RR, beats/minute) were noted from the charts.

Pulmonary function test
-----------------------

Participants underwent spirometry to evaluate pulmonary function on Days 1 and 14 postoperatively. The parameters measured included FVC, FEV~1~, FEV~1~/FVC ratio, peak expiratory flow (PEF) and forced expiratory flow between 25% and 75% of VC (FEF~25--75~).

Ethics approval and consent to participate
------------------------------------------

The study was approved by the Chang Gung Memorial Hospital review board (IRB103-0898C). Although patients' consent to review their medical records was not required by our Institutional Review Board, the patient data were kept confidential.

Statistical analysis
--------------------

We collected data on Days 1 and 14 postoperatively from electronic charts. Demographic data were analyzed using the chi-square test. A Mann--Whitney *U*-test was used to compare variables on Days 1 and 14 postoperatively. A Wilcoxon signed-rank test was used to compare variables changes on Days 1 and 14 postoperatively between COPD and non-COPD groups. Statistical significance was set at *P*\<0.05. All data were analyzed using SPSS 17.0 statistical software.

Results
=======

We enrolled 78 patients including 40 (51.2%) who had COPD and 38 (48.8%) who did not.

[Table 1](#t1-copd-13-1591){ref-type="table"} presents the descriptive demographic characteristics of the patients. Age, Acute Physiology and Chronic Health Evaluation II score, American Society of Anesthesiologists physical status, smoking index, comorbidities, preoperative medical therapy, left ventricle ejection fraction, number of coronary artery diseases and surgical types were not significantly different between the groups. There were significantly more male patients (92.5% vs 73.7%, *P*\<0.05) in the COPD group than in the non-COPD group.

[Table 2](#t2-copd-13-1591){ref-type="table"} compares the postoperative respiratory muscle strength and degree of breathlessness between the two groups. MIP (−34.52 cmH~2~O vs −43.25 cmH~2~O in the COPD group, *P*\<0.01; −34.67 cmH~2~O vs −48.18 cmH~2~O in the non-COPD group, *P*\<0.01), MEP (32.15 cmH~2~O vs 46.05 cmH~2~O in the COPD group, *P*\<0.01; 37.78 cmH~2~O vs 45.72 cmH~2~O in the non-COPD group, *P*\<0.01) and RR (20.65 breath/minute vs 17.02 breath/minute in the COPD group, *P*\<0.01; 20.65 breath/minute vs 17.34 breath/minute in the non-COPD group, *P*\<0.01) showed significant improvement after PRP in both the groups. The improvement of MIP, MEP and RR showed no significant difference between the two groups. The degree of breathlessness on the modified Borg Scale showed no significant improvement in the two groups, and neither was it significantly different between the groups (3.10 vs 2.75 in the COPD group, *P*\>0.05; 3.28 vs 2.94 in the non-COPD group, *P*\>0.05). A comparison of the postoperative pulmonary function between the two groups is shown in [Table 3](#t3-copd-13-1591){ref-type="table"} and [Figure 2](#f2-copd-13-1591){ref-type="fig"}. In the COPD group, FVC (0.85 L vs 1.25 L, *P*\<0.01), FEV~1~ (0.75 L vs 1.08 L, *P*\<0.01), peak flow (0.99 L vs 1.79 L, *P*\<0.01) and FEF~25--75~ (0.68 L vs 1.15 L, *P*\<0.01) were significantly higher on postoperative Day 14 compared to postoperative Day 1. FVC (1.11 L vs 1.36 L, *P*\<0.05), FEV~1~ (96 L vs 1.09 L, *P*\<0.05) and FEF~25--75~ (1.03 L vs 1.26 L, *P*\<0.05) were also significantly improved in the non-COPD group. However, peak flow (80.8% vs 10.1%, *P*\<0.01) and FEF~25--75~ (67.6% vs 22.3%, *P*\<0.05) in the COPD group showed a greater improvement on postoperative Day 14 than on postoperative Day 1 compared to the non-COPD group. For the prevention of gender interference, we only chose male patients for statistical analysis; the results presented in [Tables 2](#t2-copd-13-1591){ref-type="table"} and [3](#t3-copd-13-1591){ref-type="table"} are similar. Postoperative outcomes are presented in [Table 4](#t4-copd-13-1591){ref-type="table"}. The duration for which the chest tube was in place was significantly longer in the COPD group. The duration for which the pericardial drain was in place and duration of mechanical ventilation, ICU stay, hospital stay and oxygen use were not significantly different between the groups. In addition, the 30-day mortality (2.4% vs 2.7%, *P*\>0.05) and the incidence of postoperative pulmonary complications, including pneumonia (21.0% vs 17.5%, *P*\>0.05), emphysema (10.1% vs 7.8%, *P*\>0.05) and atelectasis (32.5% vs 31.4%, *P*\>0.05), were not different between the groups.

Discussion
==========

Our results demonstrated that patients with and without COPD undergoing CABG surgery with perioperative PRP showed significant improvement in respiratory muscle strength and lung function. However, PEF and FEF~25--75~ showed more significant improvement in the COPD group than the non-COPD group. Although lung function improvement in the COPD group was not significant compared with the non-COPD group, FVC and FEV~1~ showed greater percentage improvement than that in the non-COPD group. It may be due to that COPD patients have worse baseline lung function and respiratory muscle strength compared with non-COPD patients and thus COPD patients have more improvement space. This suggests that perioperative PRP is an important intervention in both COPD and non-COPD patients undergoing CABG surgery.

COPD is an important risk factor for mortality after CABG surgery. Previous studies have indicated that patients over 65 years of age with COPD have higher morbidity and mortality as well as pulmonary dysfunction after CABG surgery.[@b15-copd-13-1591],[@b21-copd-13-1591] The degree of pulmonary dysfunction related to lung volumes, VC and oxygenation is significantly reduced 2 weeks after surgery.[@b13-copd-13-1591],[@b16-copd-13-1591] Some studies have also found that FVC, FEV~1~ and FRC drop by 30%--50% during the early postoperative period.[@b13-copd-13-1591],[@b14-copd-13-1591],[@b25-copd-13-1591] However, in our study, we found that FVC, FEV~1~, PEF and FEF~25--75~ increased significantly in the COPD group after completion of the 3-week PRP. This proved that perioperative PRP is beneficial for COPD patients undergoing CABG surgery.

It is well known that CABG surgery greatly decreases respiratory muscle strength. Hulzebos et al[@b19-copd-13-1591] showed that preoperative respiratory muscle training could reduce the duration of mechanical ventilation and the incidence of pulmonary complications. Other reports also suggest reduced pulmonary complications with preoperative inspiratory muscle training.[@b11-copd-13-1591],[@b12-copd-13-1591],[@b19-copd-13-1591],[@b22-copd-13-1591] Rajendran et al reported that in patients with COPD undergoing CABG surgery, there was improvement in pulmonary function, reduced atelectasis and a shorter duration of ventilation and hospitalization after short-term pulmonary rehabilitation training.[@b7-copd-13-1591] Our study found that respiratory muscle strength had significantly improved on the postoperative Day 14 in both the groups. Besides, the RR decreased in both the groups, with no significant difference in pulmonary complications (pneumonia, emphysema and atelectasis). Thus, our findings corroborate previous reports. We only observed a significantly longer duration of chest tube placement in the COPD group.

Woods et al found that patients with COPD undergoing CABG surgery had significantly higher mortality and pulmonary complications compared to those without COPD.[@b23-copd-13-1591] Postoperative pulmonary dysfunction after CABG surgery was associated with a longer duration of mechanical ventilation, prolonged hospitalization and higher mortality in a previous study.[@b24-copd-13-1591] In contrast, we did not observe any difference in pulmonary complications and mortality between COPD and non-COPD groups in our study. Thus, PRP is an important perioperative intervention for reducing pulmonary complications and mortality in patients with COPD undergoing CABG surgery.

Our study is limited by its retrospective design; future prospective studies are needed to corroborate our findings. The external validity of our single-center study needs to be established in multicentric studies. Clinical data collection after discharge from hospital and long-term follow-up were not feasible in our retrospective study. We need more prospective studies with more participants with a longer follow-up period to validate our findings.

Conclusion
==========

Perioperative PRP interventions significantly improved respiratory muscle strength and lung function in patients with and without COPD who underwent CABG surgery. However, PRP was more effective in improving PEF and FEF~25--75~ in COPD patients than non-COPD patients. To enhance recovery, a routine administration of perioperative PRP is recommended for patients with COPD and non-COPD who undergo CABG surgery.
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![Overview of patient selection.\
**Abbreviations:** CABG, coronary artery bypass graft; PRP, pulmonary rehabilitation program.](copd-13-1591Fig1){#f1-copd-13-1591}

![FVC, FEV~1~, peak flow and FEF~25--75~ on postoperative Days 1 and 14.\
**Note:** PRP was significantly more effective in improving pulmonary function especially peak flow and FEF~25--75~ in patients with COPD (\**P*\<0.05, \*\**P*\<0.01).\
**Abbreviations:** FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; FEF~25--75~, forced expiratory flow between 25% and 75%; PRP, pulmonary rehabilitation program.](copd-13-1591Fig2){#f2-copd-13-1591}

###### 

Patient characteristics

  Variables                         COPD group (n=40)   Non-COPD group (n=38)   *P*-value
  --------------------------------- ------------------- ----------------------- ---------------------------------------------------------------------------------------------------
  Age                                                                           0.406[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤65                              20 (50.0%)          21 (55.3%)              
   ≥66                              20 (50.0%)          17 (44.7%)              
  Gender                                                                        0.026[a](#tfn2-copd-13-1591){ref-type="table-fn"},[\*](#tfn13-copd-13-1591){ref-type="table-fn"}
   Male                             37 (92.5%)          28 (73.7%)              
   Female                           3 (7.5%)            10 (26.3%)              
  Body mass index (kg/m^2^)                                                     0.406[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤24                              20 (50.0%)          17 (44.7%)              
   ≥25                              20 (50.0%)          21 (55.3%)              
  Smoking index (pack-years)        314.63 (±567.25)    122.16 (±347.14)        0.189[b](#tfn3-copd-13-1591){ref-type="table-fn"}
  APACHE II score                                                               0.449[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤13                              31 (77.5%)          28 (73.7%)              
   ≥14                              9 (22.5%)           10 (26.3%)              
  ASA physical status                                                           0.069[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤3                               28 (70.0%)          34 (89.5%)              
   ≥4                               12 (30.0%)          4 (10.5%)               
  Comorbidities                                                                 0.188[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤1                               16 (40.0%)          20 (54.1%)              
   ≥2                               24 (60.0%)          18 (45.9%)              
  Medical therapy                                                               0.558[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   Aspirin                          27 (67.5%)          20 (52.6%)              
   Calcium blocker                  2 (5.0%)            4 (10.5%)               
   Beta-blocker                     5 (12.5%)           7 (18.4%)               
   Heparin                          6 (15.0%)           7 (18.4%)               
  Ejection fraction                                                             0.285[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤30                              4 (10.0%)           7 (18.4%)               
   ≥30                              36 (90.0%)          31 (81.6%)              
  Coronary artery disease                                                       0.790[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   ≤Two-vessel CAD                  10 (25.0%)          8 (21.1%)               
   ≥Three-vessel CAD                30 (75.0%)          30 (78.9%)              
  Surgery type                                                                  0.679[a](#tfn2-copd-13-1591){ref-type="table-fn"}
   Isolated CABG                    29 (72.5%)          26 (68.4%)              
   CABG+aortic valve                6 (15.0%)           4 (10.5%)               
   CABG+mitral valve                3 (7.5%)            6 (15.8%)               
   CABG+ventricular septal repair   2 (5.0%)            2 (5.3%)                
  Basal spirometry                                                              
   FVC (L)                          2.37 (±0.71)        2.68 (±0.75)            0.093[b](#tfn3-copd-13-1591){ref-type="table-fn"}
   FEV~1~ (L)                       1.78 (±0.53)        2.22 (±0.59)            0.000[b](#tfn3-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn5-copd-13-1591){ref-type="table-fn"}
   FEV~1~% predicted                69.17 (±15.73)      91.08 (±13.35)          0.000[b](#tfn3-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn5-copd-13-1591){ref-type="table-fn"}
   FEV~1~/FVC%                      67.39 (±6.06)       78.51 (±8.88)           0.000[b](#tfn3-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn5-copd-13-1591){ref-type="table-fn"}
  FEF~25--75~%                      50.40 (±20.93)      69.19 (±14.46)          0.000[b](#tfn3-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn5-copd-13-1591){ref-type="table-fn"}

**Notes:** Comorbidities included diabetes mellitus, chronic kidney disease and hypertension.

Chi-square test.

Mann--Whitney *U*-test.

*P*\<0.05.

*P*\<0.01.

**Abbreviations:** APACHE II, Acute Physiology and Chronic Health Evaluation II; ASA, American Society of Anesthesiologists; CAD, coronary artery disease; CABG, coronary artery bypass graft; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; FEF~25--75~, forced expiratory flow between 25% and 75%.

###### 

Effect of pulmonary rehabilitation intervention on respiratory muscle strength and breathlessness

  Variables            COPD group (n=40)   Non-COPD group (n=38)                                                                                                                                                                                                                                                                               
  -------------------- ------------------- ----------------------- -------------- ---------------------------------------------------------------------------------------------------- ----------------- ----------------- -------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Muscle strength                                                                                                                                                                                                                                                                                                                              
   MIP (cmH~2~O)       −34.52 (±14.83)     −43.25 (±21.53)         25.3 (±44.0)   0.001[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   −34.67 (±13.84)   −48.18 (±23.96)   39.0 (±59.3)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   0.335[b](#tfn8-copd-13-1591){ref-type="table-fn"}
   MEP (cmH~2~O)       32.15 (±13.16)      46.05 (±21.92)          43.2 (±70.2)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   37.78 (±18.65)    45.72 (±21.57)    21.0 (±38.7)   0.003[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   0.379[b](#tfn8-copd-13-1591){ref-type="table-fn"}
  Breathlessness                                                                                                                                                                                                                                                                                                                               
   RR (beats/minute)   20.65 (±3.44)       17.02 (±1.92)           17.5 (±19.1)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   20.65 (±4.21)     17.34 (±2.22)     16.0 (±23.4)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   0.814[b](#tfn8-copd-13-1591){ref-type="table-fn"}
   Borg Scale          3.10 (±0.67)        2.75 (±1.35)            11.3 (±3.9)    0.184[a](#tfn7-copd-13-1591){ref-type="table-fn"}                                                    3.28 (±0.76)      2.94 (±1.29)      10.4 (±46.3)   0.182[a](#tfn7-copd-13-1591){ref-type="table-fn"}                                                    0.935[b](#tfn8-copd-13-1591){ref-type="table-fn"}

**Notes:**

Wilcoxon signed-rank test.

Mann--Whitney *U*-test.

*P*\<0.01.

**Abbreviations:** MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; RR, respiratory rate.

###### 

Effect of pulmonary rehabilitation intervention on pulmonary function

  Variables         COPD group (n=40)   Non-COPD group (n=38)                                                                                                                                                                                                                                                                            
  ----------------- ------------------- ----------------------- -------------- ---------------------------------------------------------------------------------------------------- ---------------- ---------------- --------------- -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  FVC (L)           0.85 (±0.29)        1.25 (±0.36)            47.1 (±44.7)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   1.11 (±0.80)     1.36 (±0.65)     22.5 (±74.8)    0.009[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*](#tfn13-copd-13-1591){ref-type="table-fn"}   0.186[b](#tfn12-copd-13-1591){ref-type="table-fn"}
  FEV~1~ (L)        0.75 (±0.32)        1.08 (±0.35)            42.7 (±57.3)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   0.96 (±0.70)     1.09 (±0.60)     13.5 (±92.7)    0.037[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*](#tfn13-copd-13-1591){ref-type="table-fn"}   0.310[b](#tfn12-copd-13-1591){ref-type="table-fn"}
  FEV~1~/FVC (%)    80.30 (±14.69)      84.92 (±10.48)          5.8 (±20.4)    0.112[a](#tfn11-copd-13-1591){ref-type="table-fn"}                                                   82.50 (±20.86)   87.07 (±14.41)   5.5 (±25.3)     0.961[a](#tfn11-copd-13-1591){ref-type="table-fn"}                                                 0.238[b](#tfn12-copd-13-1591){ref-type="table-fn"}
  Peak flow (L)     0.99 (±0.57)        1.79 (±0.80)            80.8 (±82.8)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   1.49 (±0.86)     1.65 (±1.08)     10.1 (±81.2)    0.265[a](#tfn11-copd-13-1591){ref-type="table-fn"}                                                 0.000[b](#tfn8-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}
  FEF~25--75~ (L)   0.68 (±0.37)        1.15 (±0.53)            67.6 (±64.7)   0.000[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}   1.03 (±0.74)     1.26 (±0.80)     22.3 (±104.9)   0.037[a](#tfn7-copd-13-1591){ref-type="table-fn"},[\*](#tfn13-copd-13-1591){ref-type="table-fn"}   0.043[b](#tfn8-copd-13-1591){ref-type="table-fn"},[\*](#tfn13-copd-13-1591){ref-type="table-fn"}

**Notes:**

Wilcoxon signed-rank test.

Mann--Whitney *U*-test.

*P*\<0.05.

*P*\<0.01.

**Abbreviations:** FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; FEF~25--75~, forced expiratory flow between 25% and 75%.

###### 

Postoperative outcomes in patients with and without COPD

  Variables                   COPD group (n=40)   Non-COPD group (n=38)   *P*-value
  --------------------------- ------------------- ----------------------- -----------------------------------------------------------------------------------------------------
  Chest tube (hours)          70.24 (±75.20)      14.27 (±50.74)          0.000[a](#tfn16-copd-13-1591){ref-type="table-fn"},[\*\*](#tfn14-copd-13-1591){ref-type="table-fn"}
  Pericardial drain (hours)   163.90 (±153.10)    142.66 (±95.81)         0.750[a](#tfn16-copd-13-1591){ref-type="table-fn"}
  Ventilator time (hours)     33.00 (±92.10)      10.52 (±8.98)           0.141[a](#tfn16-copd-13-1591){ref-type="table-fn"}
  ICU time (hours)            103.07 (±56.78)     84.08 (±62.78)          0.088[a](#tfn16-copd-13-1591){ref-type="table-fn"}
  O~2~ use (days)             11.44 (±3.87)       11.26 (±4.76)           0.645[a](#tfn16-copd-13-1591){ref-type="table-fn"}
  Hospital stay (days)        23.37 (±11.10)      19.80 (±7.01)           0.233[a](#tfn16-copd-13-1591){ref-type="table-fn"}
  30-Day mortality                                                        0.727[b](#tfn17-copd-13-1591){ref-type="table-fn"}
   No                         39 (97.6%)          37 (97.3%)              
   Yes                        1 (2.4%)            1 (2.7%)                
  Pulmonary complication                                                  
   Pneumonia                                                              0.604[b](#tfn17-copd-13-1591){ref-type="table-fn"}
    Yes                       7 (17.5%)           8 (21.0%)               
    No                        33 (82.5%)          30 (79.0%)              
   Emphysema                                                              0.116[b](#tfn17-copd-13-1591){ref-type="table-fn"}
    Yes                       4 (10.1%)           3 (7.8%)                
    No                        36 (89.9%)          35 (92.29%)             
   Atelectasis                                                            0.549[b](#tfn17-copd-13-1591){ref-type="table-fn"}
    Yes                       13 (32.5%)          12 (31.4%)              
    No                        27 (67.5%)          26 (68.6%)              
  Respiratory failure                                                     0.388[b](#tfn17-copd-13-1591){ref-type="table-fn"}
    Yes                       4 (9.8%)            2 (5.4%)                
    No                        36 (90.2%)          36 (94.6%)              

**Notes:**

Mann--Whitney *U*-test.

Chi-square test.

*P*\<0.01.

[^1]: These authors contributed equally to this work
